Iovance Biotherapeutics (IOVA +19.1%) is up, albeit on average volume, ahead of Phase 1 data
on the use of tumor infiltrating lymphocytes (TIL) in patients with
non-small cell lung cancer (NSCLC). The results will be presented on
Wednesday, April 28, at the American Association for Cancer Research
Virtual Annual Meeting.
The title tips the outcome: Durable complete responses to adoptive cell transfer using [TIL] in non-small cell lung cancer: a phase I trial.
The company’s core technology is TIL.
https://seekingalpha.com/news/3560606-iovance-bio-up-19-ahead-of-data-presentation-on-til-therapy-in-lung-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.